Literature DB >> 15571917

Prognostic significance of EGF receptor expression in early glottic cancer.

A N Demiral1, S Sarioglu, B Birlik, M Sen, M Kinay.   

Abstract

OBJECTIVE: A positive relationship between epidermal growth factor receptor (EGFR) expression and radioresistance has been shown both in vitro and in vivo. In a group of 31 patients with early glottic cancer treated with definitive radiotherapy, the relationship of EGFR expression with patient and tumor related parameters were analyzed and the prognostic effect of EGFR expression on local control (LC) was assessed. MATERIAL AND
METHOD: Between 1991 and 2001, 114 patients with early glottic (Tis-T2N0M0) squamous cell carcinoma were treated with radiotherapy at our institution. Among these, 31 patients whose pretreatment pathology specimens were available for immunohistochemical analysis formed the study population. Median age was 64 (46-77). Anterior commissure involvement was evident in 12 (38.7%) patients. Distribution according to T stage was as follows: Tis 6 (19.3%), T1 22 (71%), and T2 3 (9.7%). Histopathological grades of the 25 T1-2 tumors were 10/25 (40%) grade 1, 9/25 (36%) grade 2 and 6/25 (24%) grade 3. Our radiotherapy regimen was 66-70 Gy in 33-35 fractions over 6.5-7 weeks. The median follow-up period was 45 months (range, 5-116). Following immunohistochemical staining, quantitative immunohistochemistry (IHC) was performed by image analysis software and stained tumoral area percentage (STAP) was identified. The cut-off value was < or =5% versus >5%. The relationship of EGFR expression with patient (age) and tumor related (T stage, histopathological grade, and anterior commissure involvement) parameters was evaluated using chi-square test. Prognostic significance of EGFR expression, age, T stage, histopathological grade, and anterior commissure involvement on LC was assessed using log-rank test.
RESULTS: No difference was found in EGFR content distribution in relation to age, T stage, histopathological grade, and anterior commissure involvement. In the univariate analysis including age (< or =60 versus >60), T stage (Tis and T1 versus T2), histopathological grade (grade 1 and 2 versus grade 3), anterior commissure involvement (present versus absent), and EGFR expression (high versus low), only T stage and EGFR expression were found to be significant prognostic factors affecting LC (P = 0.0006 and P = 0.03, respectively).
CONCLUSION: The results of this series support that EGFR expression is an unfavorable prognostic factor in early glottic carcinomas. For this reason EGFR IHC may be considered for selecting patients for more aggressive therapies (radiotherapy with different fractionation schemes or surgery) or enrollment into trials targeting EGFR signaling pathways.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15571917     DOI: 10.1016/j.anl.2004.05.003

Source DB:  PubMed          Journal:  Auris Nasus Larynx        ISSN: 0385-8146            Impact factor:   1.863


  14 in total

1.  Sorafenib enhances the antitumor effects of chemoradiation treatment by downregulating ERCC-1 and XRCC-1 DNA repair proteins.

Authors:  Arti Yadav; Bhavna Kumar; Theodoros N Teknos; Pawan Kumar
Journal:  Mol Cancer Ther       Date:  2011-05-06       Impact factor: 6.261

2.  Epidermal growth factor receptor (EGFR) expression in patients with laryngeal squamous cell carcinoma.

Authors:  Mirko Kontić; Jovica Milovanović; Zaviša Čolović; Nikola Kolja Poljak; Željko Šundov; Ante Sučić; Valdi Pešutić-Pisac
Journal:  Eur Arch Otorhinolaryngol       Date:  2014-10-08       Impact factor: 2.503

Review 3.  Primary treatment of the anterior vocal commissure squamous carcinoma.

Authors:  Patrick J Bradley; Alessandra Rinaldo; Carlos Suárez; Ashok R Shaha; C René Leemans; Johannes A Langendijk; Snehal G Patel; Alfio Ferlito
Journal:  Eur Arch Otorhinolaryngol       Date:  2006-08-15       Impact factor: 2.503

4.  Desmoplasia measured by computer assisted image analysis: an independent prognostic marker in colorectal carcinoma.

Authors:  B Sis; S Sarioglu; S Sokmen; M Sakar; A Kupelioglu; M Fuzun
Journal:  J Clin Pathol       Date:  2005-01       Impact factor: 3.411

Review 5.  Biologically conformal treatment: biomarkers and functional imaging in radiation oncology.

Authors:  Yaacov Richard Lawrence; Maria Werner-Wasik; Adam P Dicker
Journal:  Future Oncol       Date:  2008-10       Impact factor: 3.404

6.  Renal medullary changes in renal allograft recipients with raised serum creatinine.

Authors:  B Sis; S Sarioglu; A Celik; B Kasap; S Yildiz; S Kavukcu; H Gulay; T Camsari
Journal:  J Clin Pathol       Date:  2006-02-03       Impact factor: 3.411

Review 7.  Interventions for the treatment of oral and oropharyngeal cancers: targeted therapy and immunotherapy.

Authors:  Kelvin K W Chan; Anne-Marie Glenny; Jo C Weldon; Susan Furness; Helen V Worthington; Helen Wakeford
Journal:  Cochrane Database Syst Rev       Date:  2015-12-01

Review 8.  Organ preservation surgery for laryngeal cancer.

Authors:  Sharad Chawla; Andrew Simon Carney
Journal:  Head Neck Oncol       Date:  2009-05-15

9.  Dacomitinib, an irreversible Pan-ErbB inhibitor significantly abrogates growth in head and neck cancer models that exhibit low response to cetuximab.

Authors:  Ferdows Ather; Habib Hamidi; Marlena S Fejzo; Stephen Letrent; Richard S Finn; Fairooz Kabbinavar; Christian Head; Steven G Wong
Journal:  PLoS One       Date:  2013-02-06       Impact factor: 3.240

10.  Biologic therapy in head and neck cancer: a road with hurdles.

Authors:  Pol Specenier; Jan B Vermorken
Journal:  ISRN Oncol       Date:  2012-06-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.